zurück Home | Prognose des Analkarzinoms | ||||||||
Allgemeines | 5a-OS Europa: 57% (2) | ||||||||
Differenzierung |
5a-Überleben: gut differenziert 75%, schlecht differenziert 25%. | ||||||||
Stadium |
| ||||||||
Quellen |
1.) Roohipour R, et al.: Squamous cell carcinoma of the anal canal: Predictors of treatment outcome. Dis Colon Rectum 51(2008):147-153 2.) Gatta G, Capocaccia R, Botta L, Mallone S, De Angelis R, Ardanaz E, et al.: Burden and centralised treatment in Europe of rare tumours: results of RARECAREnet- a population-based study. Lancet Oncol 2017;18:1022–39. doi 10.1016/S1470-2045(17)30445-X. | ||||||||
Impressum Zuletzt geändert am 31.12.2022 21:43